Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Biering-Sørensen, Tor
  • Sanjiv J. Shah
  • Inder Anand
  • Nancy Sweitzer
  • Brian Claggett
  • Li Liu
  • Bertram Pitt
  • Marc A. Pfeffer
  • Scott D. Solomon
  • Amil M. Shah

Aims: Left ventricular mechanical dyssynchrony has been described in heart failure with preserved ejection fraction (HFpEF), but its prognostic significance is not known. Methods and results: Of 3445 patients with HFpEF enrolled in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, dyssynchrony analysis was performed on 424 patients (12%) by multiple speckle tracking echocardiography strain-based criteria. The primary dyssynchrony analysis was the standard deviation of the time to peak longitudinal strain (SD T2P LS). Cox proportional hazards models assessed the association of dyssynchrony with the composite outcome of cardiovascular death or heart failure hospitalization. Mean age was 70 ± 10 years, LVEF was 60 ± 8%, and QRS duration was 101 ± 27 ms. Worse dyssynchrony, reflected in SD T2P LS, was associated with wider QRS, prior myocardial infarction, larger LV volume and mass, and worse systolic (lower LVEF and global longitudinal strain) and diastolic (lower e' and higher E/e') function. During a median follow-up of 2.6 (interquartile range 1.5–3.8) years, 107 patients experienced the composite outcome. Worse dyssynchrony was associated with the composite outcome in unadjusted analysis [hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.01–1.07; P = 0.021, per 10 ms increase], but not after adjusting for clinical characteristics, or after further adjustment for LVEF, AF, NYHA class, stroke, heart rate, creatinine, haematocrit, and QRS duration (HR 1.03, 95% CI 0.99–1.06; P = 0.16, per 10 ms increase). Conclusion: Worse LV mechanical dyssynchrony, assessed by speckle tracking echocardiography, is not an independent predictor of adverse outcomes in HFpEF, suggesting that mechanical dyssynchrony is unlikely to be an important mechanism underlying this syndrome. These findings warrant validation in an independent study specifically designed to assess the prognostic utility of mechanical dyssynchrony in HFpEF. Trial registration: NCT00094302.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Heart Failure
Vol/bind19
Udgave nummer8
Sider (fra-til)1043-1052
Antal sider10
ISSN1388-9842
DOI
StatusUdgivet - 2017
Eksternt udgivetJa

Bibliografisk note

Funding Information:
This work was supported by research grants from the P. Carl Petersen foundation (to T.B.-S.), The Danish Council for Independent Research Sapere Aude research talent grant (DFF-4004-00248B; to T.B.-S.), the National Institutes of Health (grant K08HL116792; to A.M.S.), and the American Heart Association (grant 14CRP20380422; to A.M.S.). TOPCAT was funded by National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD), contract HHSN268200425207C. The content of this article does not necessarily represent the views of the sponsor or of the Department of Health and Human Services. Conflict of interest: A.M.S. reports receiving research support from Novartis, Gilead, and Myocaria Inc. B.P. reports serving as a consultant for Bayer, AstraZeneca, Merck, Boehringer Ingelheim, KBP biosciences and Relypsa; and has a patent pending on site-specific delivery of eplerenone to the myocardium. N.S. reports consulting for Medtronic. M.A.P. reports receiving research grants from Amgen, Celladon, Novartis, and Sanofi Avantis; and serving as a consultant for Amgen, AstraZeneca, Bayer, DalCor Pharma UK, Genzyme, Lilly, The Medicines Company, MedImmune, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Salix, Sanderling, Sanofi, Takeda, Teva, Thrasos, and Vericel. The Brigham and Women's Hospital has patents for the use of inhibitors of the renin–angiotensin system in selected survivors of myocardial infarction with Novartis. M.A.P. is a co-inventor. His share of the licensing agreement is irrevocably transferred to charity. The other authors report no conflicts of interest.

Publisher Copyright:
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology

ID: 322955196